{"id":"neoadjuvant-nivolumab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"3-5","effect":"Pneumonitis"},{"rate":"2-5","effect":"Hepatotoxicity"},{"rate":"1-3","effect":"Colitis"},{"rate":"5-10","effect":"Hypothyroidism"},{"rate":"10-15","effect":"Rash"},{"rate":"10-15","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108738","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the PD-1 checkpoint, nivolumab restores T cell activation and proliferation, allowing the immune system to recognize and attack cancer cells more effectively. In the neoadjuvant setting, it is administered before surgery to reduce tumor burden and improve surgical outcomes while potentially enhancing anti-tumor immunity.","oneSentence":"Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:48.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neoadjuvant treatment of resectable non-small cell lung cancer"},{"name":"Neoadjuvant treatment of resectable melanoma"},{"name":"Neoadjuvant treatment of resectable esophageal or gastroesophageal junction cancer"}]},"trialDetails":[{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":156},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT02339571","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-23","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":600},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT04930783","phase":"PHASE1","title":"NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-01-03","conditions":"Melanoma, Metastatic Melanoma","enrollment":10},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT07460765","phase":"PHASE1","title":"Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-04-30","conditions":"Hnscc, Head and Neck, Squamous Cell Cancer","enrollment":40},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT03026140","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-03-29","conditions":"Colon Carcinoma","enrollment":353},{"nctId":"NCT03307616","phase":"PHASE2","title":"Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-04","conditions":"Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma","enrollment":32},{"nctId":"NCT04757363","phase":"PHASE2","title":"A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-11","conditions":"Esophagogastric Cancer, HER2-Negative","enrollment":39},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT05647265","phase":"PHASE2","title":"Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-11-27","conditions":"Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma","enrollment":26},{"nctId":"NCT04741997","phase":"EARLY_PHASE1","title":"Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-05-24","conditions":"Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation","enrollment":50},{"nctId":"NCT04610671","phase":"PHASE1","title":"Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-10-26","conditions":"Muscle-Invasive Bladder Carcinoma, Bladder Cancer","enrollment":21},{"nctId":"NCT06587451","phase":"PHASE3","title":"Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®","status":"TERMINATED","sponsor":"Sandoz","startDate":"2024-12-19","conditions":"Melanoma","enrollment":52},{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT06999980","phase":"PHASE2","title":"Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2026-02-09","conditions":"Cutaneous Melanoma, Mucosal Melanoma","enrollment":494},{"nctId":"NCT07419932","phase":"","title":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-23","conditions":"Thyroid Cancer, Thyroid Neoplasms","enrollment":120},{"nctId":"NCT03520491","phase":"PHASE2","title":"A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-04-25","conditions":"Bladder Cancer","enrollment":52},{"nctId":"NCT04606316","phase":"PHASE1","title":"Surgical Nivolumab And Ipilimumab For Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Wen, MD","startDate":"2021-02-01","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":63},{"nctId":"NCT06151236","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-03-11","conditions":"Merkel Cell Carcinoma","enrollment":20},{"nctId":"NCT07403877","phase":"PHASE2","title":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Colorectal Cancer (MSI-H)","enrollment":114},{"nctId":"NCT07398937","phase":"PHASE2","title":"Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-05","conditions":"Resectable Stage II-IIIa Squamous NSCLC","enrollment":116},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT03628209","phase":"PHASE1","title":"Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-10-03","conditions":"Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent","enrollment":21},{"nctId":"NCT06624475","phase":"PHASE2","title":"Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-08-21","conditions":"Basal Cell Carcinoma","enrollment":30},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT03661320","phase":"PHASE3","title":"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-06","conditions":"Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer","enrollment":855},{"nctId":"NCT06365619","phase":"PHASE2","title":"Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma","status":"RECRUITING","sponsor":"University of Utah","startDate":"2026-02","conditions":"Melanoma","enrollment":25},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT04229459","phase":"PHASE2","title":"Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2020-02-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT06816927","phase":"PHASE2","title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-28","conditions":"Newly Diagnosed Glioblastoma","enrollment":92},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT07141563","phase":"","title":"A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-26","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":70},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":505},{"nctId":"NCT03921684","phase":"PHASE2","title":"Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2019-04-10","conditions":"Rectal Cancer","enrollment":29},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT04933903","phase":"PHASE2","title":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","status":"RECRUITING","sponsor":"Brown University","startDate":"2021-10-05","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT07031765","phase":"PHASE1","title":"Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-07-25","conditions":"Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma","enrollment":12},{"nctId":"NCT04848116","phase":"PHASE2","title":"Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-04-24","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT06288191","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-06-21","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05672173","phase":"PHASE2","title":"Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-06-02","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":20},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT06059547","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CatalYm GmbH","startDate":"2023-09-06","conditions":"Bladder Cancer, Adult Solid Tumor","enrollment":31},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":"Advanced/Metastatic NSCLC","enrollment":350},{"nctId":"NCT02451982","phase":"PHASE2","title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03-28","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT03767582","phase":"PHASE1, PHASE2","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-12","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":46},{"nctId":"NCT07233668","phase":"NA","title":"Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-12-01","conditions":"Metastatic Renal Cell Carcinoma ( mRCC)","enrollment":172},{"nctId":"NCT02259621","phase":"PHASE2","title":"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-09","conditions":"Non-Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT07091695","phase":"","title":"Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-11","conditions":"Melanoma","enrollment":100},{"nctId":"NCT03021993","phase":"PHASE2","title":"Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2017-05-30","conditions":"Oral Cavity SCC","enrollment":17},{"nctId":"NCT04013854","phase":"PHASE2","title":"Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-01-01","conditions":"Melanoma Stage III, Melanoma","enrollment":67},{"nctId":"NCT06794229","phase":"PHASE2","title":"Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis","status":"RECRUITING","sponsor":"Qian Qin","startDate":"2025-10-30","conditions":"Locally Advanced Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT05289193","phase":"PHASE2","title":"CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-03-11","conditions":"Melanoma, Melanoma Stage III","enrollment":28},{"nctId":"NCT07013565","phase":"PHASE2","title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2025-08-07","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":20},{"nctId":"NCT04991025","phase":"PHASE2","title":"Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-10-19","conditions":"Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III","enrollment":60},{"nctId":"NCT04025879","phase":"PHASE3","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":461},{"nctId":"NCT04465643","phase":"PHASE1","title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-06-08","conditions":"Nerve Sheath Tumors","enrollment":13},{"nctId":"NCT05148546","phase":"PHASE2","title":"Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2022-04-28","conditions":"Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT03075423","phase":"PHASE2","title":"Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC","status":"COMPLETED","sponsor":"Goethe University","startDate":"2017-11-01","conditions":"Metastatic Renal Cell Carcinoma","enrollment":316},{"nctId":"NCT05472623","phase":"PHASE2","title":"Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-03-21","conditions":"Resectable Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04162015","phase":"PHASE1","title":"A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-11-12","conditions":"Malignant Pleural Mesothelioma","enrollment":22},{"nctId":"NCT07169708","phase":"","title":"A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)","status":"NOT_YET_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2026-01-31","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":100},{"nctId":"NCT07084610","phase":"PHASE2","title":"Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hospital das Clínicas de Ribeirão Preto","startDate":"2025-02-25","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07121374","phase":"PHASE1, PHASE2","title":"NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2025-07-22","conditions":"Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy","enrollment":37},{"nctId":"NCT03463408","phase":"EARLY_PHASE1","title":"Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2018-07-17","conditions":"Sarcoma","enrollment":14},{"nctId":"NCT04620200","phase":"PHASE2","title":"Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-08-11","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06754904","phase":"NA","title":"Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node","status":"RECRUITING","sponsor":"D.J. (Dirk) Grünhagen","startDate":"2025-04-23","conditions":"Melanoma, Skin","enrollment":213},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT03350126","phase":"PHASE2","title":"iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2017-12-04","conditions":"Metastatic Cancer Colorectal","enrollment":57},{"nctId":"NCT03547999","phase":"PHASE2","title":"A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC","status":"TERMINATED","sponsor":"Patrick Boland","startDate":"2018-06-26","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT02845323","phase":"PHASE2","title":"Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-05-16","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":15},{"nctId":"NCT03247712","phase":"PHASE1, PHASE2","title":"Neoadjuvant Immunoradiotherapy in Head & Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2018-01-15","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":22},{"nctId":"NCT07054086","phase":"","title":"Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT04506554","phase":"PHASE2","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2020-12-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":81},{"nctId":"NCT07050524","phase":"PHASE2","title":"Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Gastric Cancer Stage III","enrollment":80},{"nctId":"NCT05310643","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2022-05-05","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT03918252","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-02","conditions":"Mesothelioma","enrollment":30},{"nctId":"NCT06728657","phase":"PHASE2","title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","status":"SUSPENDED","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer","enrollment":68},{"nctId":"NCT03977571","phase":"NA","title":"Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-07-06","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm","enrollment":400},{"nctId":"NCT06800339","phase":"PHASE1","title":"A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-04-22","conditions":"Non-Small Cell Lung Cancer","enrollment":18},{"nctId":"NCT05180799","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioAtla, Inc.","startDate":"2022-08-03","conditions":"NSCLC, Melanoma","enrollment":320},{"nctId":"NCT06440811","phase":"","title":"Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2021-01-01","conditions":"Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":120},{"nctId":"NCT03914443","phase":"PHASE1","title":"A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Center, Japan","startDate":"2019-05-07","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06823479","phase":"PHASE2","title":"Towards Cure Via Only Ultra-short ICB in CSCC","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-05-14","conditions":"Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck","enrollment":41},{"nctId":"NCT03618641","phase":"PHASE2","title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2018-08-08","conditions":"Melanoma, Lymph Node Cancer","enrollment":34},{"nctId":"NCT03944915","phase":"PHASE2","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-08-26","conditions":"Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck","enrollment":35},{"nctId":"NCT04323046","phase":"PHASE1","title":"Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults","status":"RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2020-10-02","conditions":"Glioblastoma, Malignant Glioma, Recurrent Glioblastoma","enrollment":20},{"nctId":"NCT04331067","phase":"PHASE1, PHASE2","title":"Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-11-19","conditions":"Triple Negative Breast Cancer","enrollment":15},{"nctId":"NCT06926790","phase":"PHASE2","title":"Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-02-17","conditions":"Lung Cancer - Non Small Cell","enrollment":69},{"nctId":"NCT06926179","phase":"","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-12-01","conditions":"Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy","enrollment":500},{"nctId":"NCT05684276","phase":"PHASE2","title":"DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2023-05-12","conditions":"NSCLC, Pancoast Tumor","enrollment":22},{"nctId":"NCT03838159","phase":"PHASE2","title":"NADIM II: Neo-Adjuvant Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2019-05-15","conditions":"Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT04133948","phase":"PHASE1, PHASE2","title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-01-07","conditions":"Malignant Melanoma Stage III","enrollment":44},{"nctId":"NCT03838263","phase":"PHASE2","title":"Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2019-07-25","conditions":"Oropharynx Cancer","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":161,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Opdivo"],"phase":"phase_3","status":"active","brandName":"Neoadjuvant nivolumab","genericName":"Neoadjuvant nivolumab","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses. Used for Neoadjuvant treatment of resectable non-small cell lung cancer, Neoadjuvant treatment of resectable melanoma, Neoadjuvant treatment of resectable esophageal or gastroesophageal junction cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}